In contrast, the 2019 study targeted patients with HER2-overexpressing NSCLC, defined by immunohistochemistry (IHC) 2+ or 3+, regardless of HER2 mutation status [39]. Here, ERBB2 is linked to non-small cell lung carcinoma.